INDIA – GE HealthCare has expanded its commercial collaboration agreement with Elekta to enhance access to precision radiation therapy solutions in India.
The renewed agreement was signed by Chaitanya Sarawate, President & CEO of GE HealthCare for South Asia and Managing Director of Wipro GE Healthcare, and Manikandan Bala, Senior Vice President, TIMEA & Asia Pacific and Managing Director, India & South Africa, Elekta.
To improve access to cancer care, the two companies will make available a comprehensive offering that brings together GE Healthcare’s diagnostic solutions and Elekta’s radiation therapy solutions.
GE HealthCare and Elekta will continue to offer their own solutions using standard interoperability and facilitate interfaces with any vendor’s systems as per the terms of this renewed agreement.
In a press release, Manikandan Bala, the Managing Director at Elekta India, said: “Delivering precision radiation therapy requires advanced patient positioning, motion management technologies, and state-of-the-art radiation therapy techniques.”
Radiation therapy is an important component of cancer treatment with more than 50% of patients requiring radiotherapy as part of cancer care.
As a leading innovator of precision radiation therapy solutions, Elekta’s treatment modalities demand superior precision and accuracy in delivering radiation to the tumour while protecting surrounding healthy tissue and organs.
“Elekta’s and GE HealthCare’s combination of radiation therapy solutions and diagnostic imaging will enable healthcare providers to deliver precise and personalized therapies that treat tumours effectively while sparing adjacent tissue and organs at risk,” outlined Manikandan Bala.
This deal comes as healthcare providers continue to present patients with more personalized risk assessments, diagnoses, and treatments.
GE HealthCare’s innovative suite of diagnostic and treatment technologies are designed to help improve detection, clinical efficiency, operational efficiency, and outcomes for cancer patients.
Consequently, GE HealthCare and Elekta are working closely to overcome barriers to accessing quality cancer care for individuals in India, and in turn, enhance patient outcomes.
The new agreement is designed to provide hospitals with a comprehensive offering across diagnostic imaging and treatment for cancer patients requiring radiation therapy.
“Together, these advanced offerings are designed to improve outcomes and increase the quality of life for patients,” Manikandan Bala reaffirmed to Indian patients.
Ultimately, the joint effort aligns with Elekta’s strategic objectives to ensure hospitals and cancer centres can create seamless ecosystems that facilitate efficient end-to-end cancer care.
It is in line with the recommendation of the World Health Organization (WHO) to have one medical linear accelerator per million population in developing countries.
Similarly, GE Healthcare and Accuray Incorporated entered into a global commercial collaboration agreement to provide solutions that make it possible for more healthcare teams around the world to tailor patients’ care at every stage of their treatment journey.
Speaking on the new precision radiation deal, Chaitanya Sarawate, President & CEO of GE HealthCare’s South Asia business, said: “We continue to expand our oncology offerings through strategic collaborations in adjacent fields that are also leaders in their disciplines.”
Chaitanya Sarawate stated that GE HealthCare’s collaboration with Elekta in India is a testament to the company’s commitment to improving cancer outcomes with multiple partners and providers.
He further said that the renewed agreement builds on the significant progress made since the initial cooperation between GE HealthCare and Elekta.
“Through this collaboration with Elekta, our vision is to enable more efficient, precise, and personalized care across the cancer care continuum,” said the Managing Director of Wipro GE Healthcare.
He emphasized that GE HealthCare remains committed to providing an ecosystem where cancer care is improved by strengthening several collaborations.
He pointed out that over the years, GE HealthCare has brought together complementary solutions and technologies along the radiation therapy treatment pathway.
“We will remain focused on investments that can deliver the best cancer care, offering solutions that transform and humanize care,” underscored Chaitanya Sarawate.
What’s more, theranostics is an exciting field of molecular medicine that leverages the tumor detection properties of conventional diagnostic radiotracers to deliver radiotherapy.
The market size for theranostics applications in oncology is set to expand from US$73.1 billion in 2020 to US$119 billion by 2025.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
